F-box proteins involved in cancer-associated drug resistance (Review)

JIAN GONG, YUQIAN ZHOU, DELIANG LIU and JIRONG HUO

Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China

Received July 11, 2017; Accepted January 24, 2018

DOI: 10.3892/ol.2018.8500

Abstract. The ubiquitin proteasome system (UPS) regulated human biological processes through the appropriate and efficient proteolysis of cellular proteins. F-box proteins are the vital components of SKP1-CUL1-FBP (SCF)-type E3 ubiquitin ligases that determine substrate specificity. As F-box proteins have the ability to control the degradation of several crucial protein targets associated with drug resistance, the dysregulation of these proteins may lead to induction of chemoresistance in cancer cells. Chemotherapy is one of the most conventional therapeutic approaches of treatment of patients with cancer. However, its exclusive application in clinical settings is restricted due to the development of chemoresistance, which typically results treatment failure. Therefore, overcoming drug resistance is considered as one of the most critical issues that researchers and clinician associated with oncology face. The present review serves to provide a comprehensive overview of F-box proteins and their possible targets as well as their correlation with the chemoresistance and chemosensitization of cancer cells. The article also presents an integrated representation of the complex regulatory mechanisms responsible for chemoresistance, which may lay the foundation to explore sensible candidate drugs for therapeutic intervention.

Contents

1. Introduction
2. The ubiquitin-proteasome system
3. The F-box proteins
4. Main F-box proteins involved in chemoresistance
5. Other F-box proteins involved in chemoresistance
6. Conclusions and perspectives

1. Introduction

Cancer is a multifactorial disease and is considered as a major public health issue in both developing and developed countries (1). Due to the recent improvements in medical tools and techniques cancer death rates seem to be declining, at least for some types of cancer. However, if the bigger picture is to be considered, cancer incidence and mortality rates are still very high. Furthermore, the increased adoption of unhealthy lifestyle behaviors, such as smoking, alcohol abuse, poor diet and physical inactivity, further enhance the risk of cancer occurrence. Hence, the medical burden of cancer is increasing at a significant rate, particularly in the less economically developed countries. According to latest statistics, an estimated 14.1 million new cancer incidences and 8.2 million deaths from across the world were reported in 2012 (1).

As far as treatment and management of cancer is concerned, application of chemotherapy is quite customary. Cisplatin (DDP), which essentially functions by damaging the Deoxyribonucleic acid (DNA) of cancerous cells, had been widely used for many years in clinical settings and has shown satisfactory results. To date, cisplatin-based multidrug chemotherapy regimens remain a standard treatment method for many cancers. In the meantime, other chemotherapeutic drugs, like doxorubicin, paclitaxel, irinotecan (CPT), oxaliplatin, vincristine, hydroxyurea, rapamycin, have emerged as potential anticancer agents. In the recent years, targeted drugs such as cetuximab, trastuzumab, panitumumab and imatinib have also been identified as candidate drugs for the treatment of diverse types of cancers. However, it is noteworthy that the application of many such chemotherapeutic agents in clinical settings is limited, especially due to the development of drug resistance against them. Such conditions often lead to treatment failure and local recurrence of the disease. Considering the severity of the implications, chemoresistance in cancer has received a lot of attention by researchers and medical experts. It is not surprising that the study of chemoresistance is now considered as important as new anticancer drug development.

Drug resistance can be classified into two main categories: intrinsic and acquired (2,3). To devise methods and drugs that can overcome the effects of drug resistance, researchers have been focusing on elucidating the molecular mechanisms underlying the development of drug resistance which can further help in elucidating chemoresistance-related mechanisms and
devising methods of preventing it. The various mechanisms that were found to contribute toward the development of chemoresistance are described in Fig. 1. It is evident that factors, such as energy-dependent transporters (4), enhanced deoxyribonucleic acid repair abilities (4), drug-detoxification mechanisms (5), epithelial-mesenchymal transition (6), apoptosis evasion (7-9), cancer stem cells (CSCs) (10) as well as microRNAs (11,12), play a major role in inducing chemoresistance. However, the exact mechanisms that link these factors for bringing about resistance are yet to be elucidated. Almost all current studies on the mechanisms of chemoresistance in cancer are still in infant stage. Therefore, overcoming chemoresistance may possibly open new avenues for better treatment outcome in cancer patients (13).

2. The ubiquitin-proteasome system

Protein degradation plays a key role in maintaining cellular homeostasis. It has already been established that ubiquitin-proteasome system is crucial for protein degradation (14). It is also known to be involved in various physiological responses, like cell cycle control, DNA replication, transcription and cell signaling (15,16). Ubiquitin (Ub) is a small protein which remains covalently conjugated to lysine residues (17). Furthermore, ubiquitination and deubiquitination are complex reactions whose cellular roles are considered analogous to phosphorylation (18). The degradation of proteins by the UPS is a multi-step enzymatic process (Fig. 2) (19) that includes ubiquitin-activating enzyme (E1), ubiquitin conjugating enzyme (E2) and ubiquitin-protein ligase (E3). Human genes encode over 600 E3 ligases that participate in the ubiquitinylation of their individual targets (20). The SCF complex (21,22), which consists of four principal components: Skp1, Cul1/Cdc53, Rocl/Rbx1/Hrt1 and a F-box protein, is one of the major categories of E3 ligases. UPS regulates an array of biological processes, including tumor progression and chemoresistance. Evidently, its defective functioning is often manifested in human beings as diseases. Ubiquitination/deubiquitination is closely related to the occurrence of a wide variety of tumors.

3. F-box proteins

F-box protein has the protein-protein interaction site that determines the substrate specificity of SCF complex (23,24). It has been identified that there are 69 FBPs in the human genome. They are known to contribute to cancers since they can recognize individual targets (25). The recognizable domains beyond the F-box domain can be organized into three categories viz. WD 40 repeats (FBXW), leucine-rich repeats (FBXL) and other diverse or unknown domain-containing proteins (FBXO) (10). Then again, there are 10 members of FBXW in the human genome. FBXW1 (or β-TrCP) and FBXW7 (Cdc4) are well known FBXW. In addition, the FBXL subfamily has 21 members, FBXL1 (also known as SKP2) is a typical FBXL family protein. As far as FBXO are concerned, 38 members have been identified till yet. It is important to note that FXBO has no common substrate recognition motif. A given F-box protein can recognize more than one substrate (e.g. Skp2 targets FOXO1, RASSF1, ATF4). Similarly, one substrate can be targeted by many F-box proteins (e.g. cyclin D1 can be targeted by FBXW8 or FBXO31).

4. F-box proteins and chemoresistance

Aberrant activation of FBPs has been extensively reported in numerous cancer types, particularly in digestive system tumors (26,27). Out of the 69 FBPs, notably, only a few have been studied extensively. It has also been established that FBPs can recognize and degrade a number of oncoproteins and tumor suppressor proteins, such as p27, c-Myc and cyclin D1, including key regulators of cell death and DNA damage response. The overexpressed or downregulated FBPs can further contribute to the dysregulation of their target proteins. Therefore, the possible roles of FBPs in inducing drug resistance are just beginning to emerge. In the next section, we will discuss the recent research advances pertaining to the role of FBPs in chemoresistance and how the same can be used for directing drug discovery.

FBXW7. FBXW7, a well-established FBXW subfamily protein, was first identified in budding yeasts in the year 1973 (28). FBXW7 gene resides on human beings chromosome 4 (4q31.3) which has already been identified as a key player in the occurrence of many forms of cancers. FBXW7 mutation has been observed in 6% primary human tumors (29). Mutations in FBXW7 lead to the rapid accumulation of degradable proteins, which in turn facilitates tumor progression (30). It is therefore obvious that FBXW7 plays crucial tumor suppressor functions in many tumors. FBXW7 primarily exerts its antitumor functions by regulating the degradation of an entire network of proteins, including cyclin E (31), c-Myc (32), c-Jun (33), Notch (33), presenilin (34), (myeloid cell leukemia-1) Mcl-1 (35), many of which have oncogenic functions. Mutated FBXW7 is also known to mediate the stabilization of oncoproteins in tumors and thus causes induction of chemoresistance (36,37). Therefore, the downregulation of FBXW7 protein levels may contribute to the tumor progression and chemoresistance.

FBXW7 and chemoresistance. FBXW7 has already been categorized as a chemoresistance-related gene. Mounting evidences show that FBXW7 genetic status has an intricate relationship with chemotherapeutic drug resistance in cancer patients. Therefore, FBXW7 is proposed as a promising therapeutic target to improve sensitivity and efficacy of chemotherapeutic drugs. Wertz et al (37) have already reported that loss of FBXW7 led to increased resistance of colon cancer cells towards taxol. On the other hand, inhibition of Mcl-1 was found to restore the cancer cells' sensitivity toward taxol and vincristine-induced cell death. Mcl-1, a key pro-survival BCL2 family member, is known to be involved in mitotic arrest. This further indicates that there exists a molecular link that forms the basis of antitubulin agent resistance and chemotherapy induced polyplody. Hence, Mcl-1 degradation can be implied for the development of targeted therapeutic methods intended towards the eradication of colon cancer cells (38). Detailed analysis has shown that FBXW7 mutations in colorectal cancer cells are responsible for blocking Mcl-1 degradation and thus mediating the development of resistance of against targeted therapies (regorafenib) (39). In consistent
with the results observed in colon cancer cell lines, FBXW7 ablation in ovarian cancer cells was also found to inhibit c-Myc degradation. This makes the cells more resistant to vincristine-induced cell death. The above mentioned research
studies on the one hand showcased the key roles of FBXW7 in inducing therapeutic effects of the chemotherapeutic drugs, while on the other hand, they also provided the much needed information for identifying the possible ways to increase the sensitivity of cancer cells to vincristine. Inuzuka et al (35) also found that E3 ubiquitin ligase SCF (FBXW7) plays key regulatory roles in cellular apoptosis by targeting McI-1 for ubiquitylation in a manner which depends on phosphorylation by glycogen synthase kinase 3. Notably, loss of FBXW7 and the resultant subsequent higher levels of McI-1 were found to increase the sensitivity of cancer cells to the targeted therapy drug sorafenib. However, it was observed that these cells acquired resistance to the Bcl-2 family inhibitor ABT-737 in T-acute lymphoblastic leukaemia (T-ALL) cells.

In addition, multidrug resistance-associated protein (MRP) is also found to be closely related to FBXW7 in nasopharyngeal carcinoma (NPC) cells. MRP makes FBXW7-deficient cells more resistant against antitumor drug DDP. Conversely, upregulation of FBXW7 expression restores CDDP chemosensitivity in these cells (40). Cryptochrome 2 (CRY2), a circadian clock protein, is another such protein which is overexpressed in chemoresistant colorectal cancer cells (40). Fang et al (41) proved that CRY2 is one of the direct targets of FBXW7 in DLD-1 and SW480-colorectal cancer cell lines too. Furthermore, cells with low levels of expression of CRY2 were found to be more sensitive to oxaliplatin. It has also been proved that FBXW7 mutation in T cell acute lymphoblastic leukemia (T-ALL) causes stabilization of c-Myc, which is the Notch-1 target. Due to these reasons these cells were found to be more resistant to γ-secretase inhibitor treatment (42).

The findings of the study conducted by O’Neil et al (43) in 2007 were also found to be in agreement with the report of Thompson et al (42), which indicated that FBXW7 ablation increased resistance to γ-secretase inhibitors in leukemic cells via Notch pathway activation. Both the studies indicated that patients harboring FBXW7 mutation were more resistant to treatment with GSI. It can thus be concluded that FBXW7 inactivation had relationship with chemotherapeutic drugs by its diverse targets. Although many chemoresistance targets of FBXW7 have been identified in different types of cancer cells, it still remains enigmatic that which one is the most relevant.

A more recent study showed that inhibitor of growth 5 (ING5)-mediated chemoresistance is also positively associated with FBXW7 hypopexpression (44). It was found that ING5 overexpression increased U87 cells' chemosensitivities towards cisplatin, MGI32, paclitaxel and suberoylanilide hydroxamic acid (SAHA). Further studies indicated that ING5-associated chemoresistance may be the result of dysfunction of Akt and NF-κB pathways. Furthermore, epithelial-mesenchymal transition (EMT) is one of the main factors responsible for the induction of chemoresistance. Notably, FBXW7 is known to play a central role in controlling the EMT in cancer cells (45). Reduced expression of FBXW7 is proposed to reduce the polarity and adherent junctions of cells, promote tumor cell invasion and migration, thus resulting in reduced chemosensitivity of non-small-cell lung cancer cells towards cisplatin (45).

Cancer stem cells (CSCs) are another facet of the molecular mechanism of chemoresistance. It has been observed that destruction of the CSCs can be an effective strategy for improving chemotherapeutic effects of anticancer agents. Some highly intricate multidimensional studies indicated that FBXW7 also plays a crucial role in the maintenance of both normal stem cells and cancer-initiating cells (CICS) (46). Evidently, FBXW7-deficient leukemia-initiating cells (LICS) were more found to be resistant against conventional chemotherapy, but sensitive to imatinib. Studies conducted in cancer mouse models revealed that combining FBXW7 genetic ablation and imatinib is more effective than any of these strategies applied alone (47). When all these aspects are considered together, it becomes apparent that FBXW7 plays prominent role in the induction of chemoresistance in cancer cells.

Despite the innumerable number of studies conducted on FBXW7, little is known about the regulatory mechanisms that control the molecular pathways leading up to FBXW7 induced chemoresistance. As far as the possibility and scope of applicability of FBXW7 in devising therapeutic strategies against cancer is concerned, it has been observed that tumor suppressor gene p53 directly targets FBXW7 and promotes the transcription of FBXW7 mRNA (48). Recently, upstream regulators like EBV Nuclear Antigen (EBNA1)-binding protein 2 (Ebp2) (49), CCAAT/enhancer-binding protein-δ (C/EBPδ) (50), microRNA (miRNA)-27a (51) were identified. It has thus been proposed that all these referred proteins or miRNAs can be candidate targets that can be implicated to increase drug sensitivity, particularly by targeting FBXW7. Increasing number of research studies are indicating that miRNAs have regulatory roles in the process of tumor progression that are particularly attributed to chemoresistance or radioresistance. In addition, it has also been elucidated that FBXW7 is directly regulated by the dysregulation of microRNA pathway. MicroRNAs, such as miR-25 and miR-223, play essential role in regulating FBXW7, particularly by reducing their mRNA levels (52). miR-223 is an oncogenic microRNA and highly expressed in human erythroleukemic cell line K562 (52). miR-223/FBXW7 pathway received increased attention, especially after the discovery of the possible implications of miR-223/FBXW7 as an efficient therapeutic target for overcoming chemoresistance. In the past three years alone, three separate research studies have independently identified miR-223/FBXW7 as a key signal pathway involved in chemoresistance. The study conducted by Zhou et al (53) showed that miR-223 could promote DDP resistance in gastric cancer cells by downregulating FBXW7. Notably, low expression of FBXW7 contributed to cell cycle arrest and apoptosis. In support of this notion, miR-223 inhibitor can significantly upregulate the expression of FBXW7 mRNA and protein in 7901/DDP cells (gastric cancer cell line). Conversely, miR-223 mimic can downregulate the expression of FBXW7 mRNA and protein. Further analysis of the same indicated that the overexpression of miR-223 induced significant increase of the expression and activity of cyclin E, while reduced miR-223 expression led to increased FBXW7 expression and decreased cyclin E activity. Yet, another study that was conducted by Li et al (54) demonstrated that miR-223/FBXW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. miR-223/FBXW7 pathway has also been investigated for drug resistance in cancers (38,55-57). FBXW7 mutation drives acquired resistance to targeted agents cetuximab or panitumumab (58).
Eto et al (59) were the first to report that the overexpression of miR-223 decreases FBXW7 expression and the sensitivity of gastric cancer cells to trastuzumab. These studies provided important insights into the possibility of application of miR-223/FBXW7 as a biomarker that can be used to estimate the efficacy of DDP-based chemotherapy. However, in order to do so it is imperative that the upstream stimuli and downstream targets of the above-mentioned pathway are studied in detail. As of now, it is said that almost all of the relevant studies indicate that FBXW7 is a chemosensitizer in cancer cells, which when lost enhances the risk of chemoresistance.

SKP2. In 1995, the Beach group discovered that S phase kinase-associated protein 2 (SKP2) gene is located on the 5p13 chromosome (60). Since then, numerous studies have highlighted its oncogenic roles (61-64). Furthermore, the overexpression of SKP2 has been reported in many tumor types (65-69). These results are a clear indication that SKP2 has significant impact on the progression of tumors and also induction of drug resistance in different types of cancer cells.

SCF SKP2 is a multicompontent RING-type E3 ligase that targets and degrades many tumor suppressor proteins, such as p27, p16, p21, p57, E2F-1, TOB1, RBL2, cyclin D/E, BRCA2, FOXO1 and RASSF1A, and regulates numerous cellular processes. As cell cycle regulation is a key mechanism by which most chemotherapy agents exert their cytotoxic effect, their alterations are likely to have major implications in the drug induced responses (70). When collectively studied, these studies clearly indicated that SKP2 is an oncoprotein and also the chief regulator of cell cycle inhibitor p27\(^{kip}\), which is known as a cell cycle protein that is involved in tumor progression. It was thus proposed that SKP2 may also be associated with chemoresistance (71). The present article reviewed the available information regarding the possible roles of SKP2 towards the induction of chemoresistance. The authors hope and desire that the information presented in here is implicated towards achieving a better treatment outcome for the chemoresistant subset of human cancer patients.

SKP2 involved in chemoresistance. SKP2 supposedly interacts with a variety of substrates that determine the outcome of chemoresistance in cancer cells. SKP2 is known to act as an oncoprotein that also has close correlations with paclitaxel sensitivity, which is especially brought about in human lung cancer cells by regulating Mad2 via p27\(^{kip}\)-p53 (72). Patients with high levels of expression of SKP2 show that small molecule inhibitors of SKP2 combine paclitaxel and bring about better lung cancer treatment responses (72). High levels of expression of SKP2 is a recognized biomarker for poor prognosis in cancer. Davidovich et al (73) revealed that high levels of SKP2 are known to have poor response towards preoperative doxorubicin-based chemotherapy in breast cancer patients in 2008 (73). Furthermore, SKP2 expression not only contributes to drug resistance but also extrinsic induction of apoptosis. It has also been shown that high levels of expression of SKP2 in pancreatic ductal adenocarcinoma cell lines makes them resistant towards the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Hence, SKP2 expression levels can be considered as a key determinant of antitumor responses to mTOR inhibitors. In addition, overexpression of SKP2 also increases cellular resistance to rapamycin (75). Furthermore, SKP2 determines sensitivity of tumor xenograft to rapamycin, which highlights it as a potential pharmacogenomic marker that can predict therapeutic sensitivity of the cells towards rapamycin.

Study of SKP2 in relation to target therapy indicated that SKP2 deficiency enhances herceptin sensitivity in Her2-positive cancer cells and tumors (76). Except for FBXW7, SKP2 is yet another F-box family protein that forms the SKP2 SCF complex, which functions for the regulation of stem cells. Hematopoietic stem cells, that are the most critical factors in prevention of bone marrow failure in humans, are also regulated by SKP2.

It has also been studied that SKP2 deficiency leads to elevated cyclin D1 expression levels, which in turn contribute to increase hematopoietic stem cell cycling. Doing so enhances sensitivity of leukemia cells towards other chemotherapeutic agents, such as cyclophosphamide, 5-FU, and DOX (77). All the above described data highlight the central role of SKP2 in chemoresistance. It is also proposed that SKP2 may be used as a biomarker to identify those patients who are likely to respond to doxorubicin in a more effective manner.

5. Other F-box proteins involved in chemoresistance

\(\beta\)-TrCP, \(\beta\)-TrCP (FBXW1), \(\beta\)-transducin repeats-containing proteins, is a representative of the FBXW family. IκBα and \(\beta\)-catenin are two well-characterized substrates of \(\beta\)-TrCP, thus \(\beta\)-TrCP is linked closely to tumorigenesis and development (78). IκB is the inhibitor of NF-κB, which always functions as a tumor suppressor. \(\beta\)-catenin is a downstream molecule of Wnt signaling pathways. Notably, \(\beta\)-TrCP acts as an oncoprotein in colorectal cancer, but it is known to act as a suppressor in gastric cancer. The simultaneous elevation of NF-κB activity with elevated \(\beta\)-TRCP1 expression indicate that it can be considered as a contributor to chemoresistance towards anticancer drug etoposide in pancreatic carcinoma cells (79). Furthermore, cyclin D1 overexpression is also related to chemoresistance in cancer cells.

Berberine (BER) is a traditional Chinese drug, which is essentially an isoquinoline alkaloid purified from the Berberis species. It has been reported that the drug possesses multiple functions including enhancing chemotherapy sensitivity in cancer (80). Berberine functions by inhibiting cyclin D1 expression in human hepatoma cells HepG2 and MHCC97L via the ubiquitin-proteasome signal pathway. Berberine promotes the phosphorylation of cyclin D1 at the T286 site and then accelerates binding of \(\beta\)-TrCP to cyclin D1 thus mediating its degradation. It was thus apparent that knockdown of \(\beta\)-TrCP expression could reduce this phenomenon (81). On the other hand, Nrf2 is a newly identified substrate of \(\beta\)-TrCP (82). Nrf2 is controlled by two distinct \(\beta\)-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity (83). Furthermore, overexpression of Nrf2, nuclear factor (erythroid-derived-2)-like 2, increases resistance to the chemotherapeutic drug in breast cancer, acute myeloid leukemia and pancreatic cancer (84-86). However, the molecular mechanism between them remains further elucidated.

In multiple myeloma cell lines, DEP-domain containing mTOR-interacting protein (DEPTOR), another endogenous
mTOR inhibitor, is inversely correlated with cell's responsiveness to anticancer drugs, such as rapamycin, velcade, paclintaxel, via modifying the mTOR pathway. The degradation of DEPTOR is mainly controlled by β-TrCP, which gives us a clue that the dysregulation of β-TrCP directly affects the response of patients to chemotherapeutic agents (86). Sp1, specificity protein 1, is another agent enhances temozolomide resistance in glioblastoma (87). Doxorubixin stimulus causes the high expression of β-TrCP in breast cancer cell line MCF-7, which promoted Sp1 degradation. Therefore, upregulation of β-TrCP is likely to increase doxorubicin-induced cell apoptosis (88). The role of β-TrCP in determining chemoresistance is mainly through its diverse substrates which are involved cell death.

**FBXL5 and FBXL7.** FBXL5, a critical regulator of iron homeostasis, also plays crucial roles in cancer. Although little is known about its role in chemoresistance, Wu et al (89) explored the effects of expression of FBXL5 on anticancer drug sensitivity. In contrast, Rho GTPase dissociate inhibitors 2 (RhoGDI2), is known to be associated with cisplatin resistance, which is mainly influenced by upregulation of Bcl-2 expression and reduction of cell apoptosis in gastric cancer cells (90). It has also been observed that Cho group use immunoprecipitation assay is highly efficient in elucidating the interaction between FBXL5 and RhoGDI2. The exogenous overexpression of FBXL5 increases the sensitivity of cisplatin through Erk and p38 pathway in RhoGDI2 high-expressed gastric cancer cells (88). Furthermore, single nucleotide polymorphisms (SNPs) in the FBXL7 gene are also associated with the increased breast cancer risk (91). This can be correlated with the fact that FBXL7 has been shown to induce the ubiquitylation of Aurora kinase A (92) and survivin (93) in a cell cycle-independent manner. Notably, Kamran et al (94) found that overexpression of Aurora kinase A negatively regulated FBXL7, leading to anti-apoptotic protein survivin accumulation and doxorubicin resistance in gastric cancer.

**FBXO5, FBXO6, FBXO15, FBXO18, FBXO21, FBXO22 and FBXO32.** Overexpression of FBXO5 is frequently considered as a potential oncogenic factor (95,96). Shimizu et al used small interfering RNA knockdown method to further explore the mechanism of doxorubicin resistance on FBXO5 accumulation. The results thus obtained indicated that the downregulation of FBXO5 enhanced the induction of apoptosis by doxorubicin, but not taxol. However, no synergistic effect of FBXO5 knockdown in combination with doxorubicin treatment was found in normal cells. Therefore, inhibition of FBXO5 function can be considered useful for enhancing sensitivity of cancer cells to chemotherapeutic drugs and ionizing radiations (97).

FBXO6 has been suggested as a potential biomarker for predicting anticancer drugs responsiveness. Checkpoint kinase 1 (Chk1), one of key components of the replication checkpoint response to DNA damage response, which was found to be inversely correlated with FBXO6 in human breast tumor tissues. Zhang et al (98) proposed that FBXO6 promotes the degradation of Chk1 and a defect in this mechanism may be responsible for increasing tumor cell resistance to certain anticancer drugs CPT. It was further suggested that the forced expression of FBXO6, but not Skp2, in the CPT-resistant cells promotes the degradation of endogenous levels of Chk1. Such cells exhibited strong staining for the caspase-3 cleavage product after CPT treatment. In contrast, depletion of FBXO6 decreased the CPT sensitivity in lung cancer cell line A549, which was completely restored by depletion of Chk1.

P-glycoprotein (P-gp), a multidrug resistance transporter that effluxes chemotherapeutic drugs, is a major cause of chemotherapy failure. FBXO15 knockdown causing P-gp accumulation enhanced vincristine resistance (99). CD44 can increase P-gp protein stability and promote drug resistance. Ravindranath et al (100) reported the mechanism between them. CD44 can protect P-gp from FBXO21 mediated degradation, thus leading to inducing resistance against valinomycin. In addition, CD147 and type I transmembrane glycoprotein have positive regulatory effects on P-gp expression. FBXO22 mediates the polyubiquitination and degradation of CD147, thus involving drug resistance. Low level of FBXO22 contributes to the accumulation of CD147, thereby inducing cisplatin resistance in non-small-cell lung carcinoma cell line A549/DDP cells (101).

FBXO32 is also well recognized since its upregulation during skeletal muscle atrophy (102), which is known to negatively regulate epithelial to mesenchymal transition in platinum resistant-urothelial carcinoma cells (103). Furthermore, FBXO32 enhances chemosensitivity to cisplatin by inducing
apoptosis in ovarian cancer cells (104). Although many FBXO family proteins involved in chemoresistance, for example, FBXO15 and FBXO21, can regulate P-gp ubiquitination, the question that remains is that “which one of them is the most prominent determinant of chemoresistance?” Hence, further investigation that are intended towards accurate determination of the possible roles of FBPs in chemoresistance are warranted.

6. Conclusions and perspectives

The present article presents an unprecedented immaculate review of multiple facets of dysregulated expression of FBPs in human cancer cells, their possible roles in regulation of substrate turnover, their possible implications in inducing chemoresistance against anticancer drugs, such as cisplatin, doxorubicin, paclitaxel, CPT, oxaliplatin, vincristine, hydroxyurea, rapamycin, trastuzumab and imatinib (Fig. 3). Analyses of the results of multiple number of studies indicated that reconstitution of the function of FBPs could restore the sensitivity of tumor cells to the given chemotherapeutic agents. Organoids models have been used for testing FBXW7-associated drug response (105). FBXO31, which is considered as a potential tumor suppressor protein in both liver cancer and gastric cancer (106,107), is known to induce DNA damage and promote cyclin D1 degradation. Contrary to the results obtained from studies conducted on liver cancer and gastric cancer, FBXO31 in esophageal cancer is known to be overexpressed (100). Notably, studies conducted in our laboratory have demonstrated that FBXO31 is tightly correlated with incurring drug resistance in esophageal cancer. The data generated by us have showed that high expression of FBXO31 in esophageal cancer cell lines promotes cisplatin resistance through MAPK signal pathway (108). Therefore, FBPs can be considered as possible targets for reversing the occurrence and effects of chemoresistance. It is expected that these findings may contribute to study of chemoresistance in individualized cancer treatment methods. Although some progress has been made, further investigations are urgently warranted.

Notably, until now, no compounds that can directly target FBPs have been reported. Among the 69 FBPs that have been identified, most studies centered on FBXW7, SKP2 and β-TrCP. Bortezomib is a proteasome inhibitor which has been approved by the FDA and successfully used in the treatment of hematologic malignancies (109,110). It is proposed that it can be used to design the disease-specific components of UPS inhibitors. FBPs, such as the ones described in the preceding sections, are beginning to show therapeutic potential in the field of chemosensitivity. However, there are still many important questions that need to be addressed in future studies. For example, many FBPs have opposite functions in different cancer types. FBXO31 acts as a tumor suppressor in breast cancer or gastric cancer, but have oncogenic activity in esophageal cancer. Owing to the vast diversity of the substrates it interacts with, it is not uncommon that FBPs have multiple implications in cancer drug resistance. Although many of these substrates have been identified, the ones that are specifically related to drug resistance are yet to be elucidated. Furthermore, such diversity of substrates also raises questions on whether a given F-box protein can exert both chemoresistant and chemosensitive roles in the same tissue? Despite extensive studies, our understanding on the impact of FBPs in drug resistance is still limited. It is therefore recommended that in-depth investigation on this must be conducted so that critical players that are involved in mediating drug resistance can be identified.

Acknowledgements

JG, YQZ, DLL and JRH are grateful for the Fundamental Research Funds from the Science And Technology Plan Of Hunan Province (grant no. 2013SK3033).

References


